Human regular U‐500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aim: To compare the safety and efficacy of U500‐R delivered by a novel, specifically designed U500‐R insulin pump with U‐500R delivered by multiple daily injections (MDI). Methods: The phase 3 VIVID study randomized people with type 2 diabetes to U‐500R by continuous subcutaneous insulin infusion (CSII) or MDI. Participants (aged 18–85 years) had HbA1c ≥7.5% and ≤12.0% and a total daily dose of insulin >200 and ≤600 U/day. After a 2‐week transition to three times daily injections of U‐500R, participants were treated for 24 weeks with U‐500R by CSII or MDI. Treatment arms were compared using mixed model repeated measures analysis. Results: The study randomized 420 participants (CSII: 209, MDI: 211) with 365 completers. Mean changes from baseline were: HbA1c, −1.27% (−13.9 mmol/mol) with CSII and −0.85% (−9.3 mmol/mol) with MDI (difference − 0.42% [−4.6 mmol/mol], P <0.001); fasting plasma glucose, −33.9 mg/dL (−1.9 mmol/L) with CSII and 1.7 mg/dL (0.09 mmol/L) with MDI (difference − 35.6 mg/dL [−2.0 mmol/L], P <0.001); total daily dose, 2.8 U with CSII and 51.3 U with MDI ( P < 0.001). Weight changes and rates of documented symptomatic and severe hypoglycaemia were similar between groups; the CSII group had a higher rate of nocturnal hypoglycaemia. Conclusions: In type 2 diabetes requiring high doses of insulin, both methods of U‐500R delivery lowered HbA1c. However, the CSII group attained greater HbA1c reduction with significantly less insulin. Individualized dose titration will be important to balance glycaemic control with hypoglycaemia risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters‐Weijnen, C., Forsén, T., Galstyan, G., Geelhoed‐Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12689 · Cited by 276
Purnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
Herman, W. H., Ilag, L. L., Johnson, S. L., Martin, C. L., Sinding, J., Al Harthi, A., Plunkett, C. D., LaPorte, F. B., Burke, R., Brown, M. B., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1568 · Cited by 265
Self-citationde la Peña, A., Riddle, M., Morrow, L. A., Jiang, H. H., Linnebjerg, H., Scott, A., Win, K. M., Hompesch, M., Mace, K. F., Jacobson, J. G., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0721 · Cited by 125
Clinical use of U-500 regular insulin: Review and meta-analysis
Reutrakul, S., Wroblewski, K., & Brown, R. L. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600229 · Cited by 94 · cited 2×
“Previous studies of U-500R in CSII therapy lacked controls, were mostly retrospective, or included a small number of subjects.(2,9) Therefore, the use of U-500R by CSII needed to be studied in a larger, prospective, randomized clinical trial.”
BackgroundMethodHood, R. C., Arakaki, R. F., Wysham, C., Li, Y. G., Settles, J. A., & Jackson, J. A. (2015) · Endocrine Practice · doi:10.4158/ep15612.or · Cited by 61
Cited by
Forlenza, G. P., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., McGill, J. B., Umpierrez, G., & Aleppo, G. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0206 · Cited by 70
Concentrated insulins: Clinical update of therapeutic options
Umpierrez, G. E., Holt, E. H., Einhorn, D., & McGill, J. B. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0607 · Cited by 44
Regittnig, W., Tschaikner, M., Tuca, A., Simic, A., Feiel, J., Schaller‐Ammann, R., Licht, A. H., Jungklaus, M., & Pieber, T. R. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14594 · Cited by 27
Jendle, J., & Reznik, Y. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15087 · Cited by 26
Hood, R. C., Borra, S., Fan, L., Pollom, R. D., Huang, A., & Chen, J. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.05.006 · Cited by 9
Self-citation
Metadata
- Authors
- Grunberger, G., Bhargava, A., Ly, T., Zisser, H., Ilag, L. L., Malone, J., Fan, L., Zhang, S., & Johnson, J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-01-26
- Volume
- 22
- Issue
- 3
- Pages
- 434-441
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2996374979
- Cited by
- 44
- References
- 7
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.